NOT TRANFERABLE

TENDER NO. :- BPPI/Drugs Testing/17

TENDER FOR EMPANELMENT OF DRUGS TESTING LABORATORIES FOR ANALYSIS OF DRUGS & MEDICINES FOR 2015-2017

Dated: 04.03.2015

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA
(Set up under the Department of Pharmaceuticals, Govt. of India)
IDPL CORPORATE OFFICE, IDPL COMPLEX, DUNDAHERA, GURGAON 122016
Telephone: **0124-4303751/56**; Fax: **0124-2340370** Website: **janaushadhi.gov.in**

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA (BPPI)
(SET UP UNDER THE DEPARTMENT OF PHARMACEUTICALS, GOVERNMENT OF INDIA)
Regd. Office: Core No. 6, First Floor, SCOPE Complex, Lodi Road, New Delhi-110003
Working Office: IDPL CORPORATE OFFICE, IDPL COMPLEX, DUNDAHERA, GURGAON (HR)

TENDER FOR EMPANELMENT OF DRUGS TESTING LABORATORIES FOR ANALYSIS OF DRUGS & MEDICINES FOR 2015-2017

Important Dates:	
Tender Reference Number	BPPI/Drug Testing/017 Date 04/03/2015
Date of availability of Tender documents on website	04/03/2015(Wednesday)
Last date and time for receipt of Tender	25/03/2015(Wednesday)15.00 hrs
Date and time of Opening of Tender	25/03/2015(Wednesday)15.30 hrs
Place of Opening of Tender	BPPI, IDPL Corporate Office, IDPL Complex, Dundahera, Gurgaon (HR)
Address For Communication	BPPI, IDPL Corporate Office, IDPL Complex, Dundahera, Gurgaon (HR)-122016
Contact Person for clarification if any:	
1. Mr. K. Chopra, Director (Operation & Marketing) Phone: 0124-4040759, Mob: 9711003043 Email: kchopra.bppi@gmail.com	2. Mr. Mahadev Agarwal, Manager (Regulatory) Phone: 0124-4556756, Mob: 9873294473 Email: mahadevpharm.bppi@gmail.com

CONTENTS

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA

(Set up under Department of Pharmaceuticals, Govt. of India)

TENDER FOR EMPANELMENT OF DRUGS TESTING LABORATORIES FOR ANALYSIS OF DRUGS & MEDICINES FOR BPPI FOR TWO YEAR (2015-17) FROM THE DATE OF ACCEPTANCE OF TENDER

"CONFIDENTIALITY IS THE ESSENCE OF THIS TENDER"

1. Sealed tenders are invited till 25/03/2015 Wednesday (15.00 hours) by **General Manager (A&F) at Bureau of Pharma Public Sector Undertakings of India (BPPI), IDPL Corporate Office, IDPL Complex, Dundahera, Gurgaon-122016 (Haryana)**, **(Herein referred as Tender inviting authority unless the context otherwise requires)** for empanelment of approved drug testing laboratories (under Drugs & Cosmetics Act 1940 & Rules 1945) which are GLP compliant (as per Schedule L1) and NABL accredited for drugs requiring Chemical/Physico-chemical, instrumental and microbiological testing facilities **for a period of two years** from the date of acceptance of tender by BPPI. The agreement may be extended for further period on mutually agreed terms.

The complete set of tender document can be downloaded from the BPPI website **janaushadhi.gov.in** and **pharmaceuticals.gov.in** free of cost**.**

NOTE:- LATE TENDER IS NOT ACCEPTABLE

2. Eligibility Criteria:

(a). National Accreditation Board for Testing and Calibration Laboratories (NABL) accredited analytical laboratories having approval/license under the Drugs and Cosmetics Act and Rules 1945 with minimum two years experience in the analysis of DRUGS & MEDICINES with an minimum average annual turnover of Rs. 30 Lakhs for last two years (Govt./CPSU's Laboratories, Research and Development Laboratories, Laboratories run by Co-operative body and Educational Institutions are exempted from the turnover criteria) ***however turnover for the year 2013-14 should not be less than Rs. 30 lakhs, are eligible to participate in the tender***. Agents are not eligible to participate in the tender.

(b). Drug Testing Laboratory which is also engaged in manufacturing of medicines and participate in drug procurement as well as drug testing Laboratory tender shall not be considered for testing laboratory empanelment as eligible if their product achieve L-1 rate in any drug procurement tender by BPPI.

(C). Drug Testing laboratories should have Approval/ license under Drugs & Cosmetics Act and Rules 1945 , with two years standing in the analysis of Drugs & Medicines.

(d). Drug Testing laboratories should be GLP compliant under the provisions of Drugs & Cosmetics Act 1940 and Rules 1945 and should hold Schedule L1 certificate.

(e). Drug Testing laboratories should not have been banned/debarred/ black listed by any State or Central Govt. Organizations or its procurement agencies on the due date of bid submission.

(f). Drug Testing laboratory and its responsible persons should not have ever been convicted under the D & C Act 1940 and Rules 1945.

(g). Drug Testing laboratory should have all necessary instruments/equipments and required mandatory facilities for testing/analysis of Drugs and Medicines as per statutory requirement for which it is participating in the tender.

(h) Attested copy of approval and GLP Certificate of Drug Testing laboratory, duly renewed up to date issued by the state licensing authority be submitted.

3. Technical bid – Cover -'A' including Earnest Money Deposit & other Documents:

The tenderer must submit the following documents in the sealed cover super scribed **Cover -'A'** (all the documents have to be sealed and copies have to be self attested and notarized in all pages).

[a]. The Earnest Money Deposit (EMD) shall be Rs.10,000/-(Rupees Ten Thousand only) paid in the form of **Demand Draft drawn** in favour of **BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA** payable at Delhi/Gurgaon, should be sent with tender form in Cover-'A'. The EMD is refundable however it will not earn any interest. EMD in the form of cheque/ cash/ postal order/ e-payment will not be accepted.

The EMD amount of unsuccessful bidder will be refunded to them within 30 days of finalization of tender. In respect of successful bidder (empanelled bidder), the EMD amount will be adjusted towards security deposit.

[b]. Self attested and notarized photocopies of Approval/ license issued by State Licensing Authority duly renewed up to date and NABL accreditation certificate.

[c]. Documentary evidence of having analyzed DRUGS & MEDICINES for the last two years with the statement in the performa given in Annexure-I

[d]. Self attested and notarized photocopy of certificate of registration for Service Tax should be enclosed in Annexure-II

[e]. Self attested and notarized document of the following should be furnished in the format given in Annexure-III

(i). List of qualified personnel employed in Drug Testing laboratory along with their qualification, experience and details of their approvals (copy of the approval).

(ii). List of sophisticated instruments (working condition) available in Drug Testing laboratory.

(iii). Facilities available in Microbiological Section in the laboratory

[f]. A declaration in the Performa given in Annexure-IV duly signed and notarized.

[g]. Details of DRUGS & MEDICINES to be analyzed to be given in Annexure-V

[h]. Documentary evidence regarding constitution of Drug Testing laboratory viz. Memorandum and Articles of Association, partnership deed etc, with details of name, address, telephone no., fax no., e-mail address of Managing Director/ Partner/ Proprietor etc.

[i]. The instruments such as power of attorney, Resolution of Board etc authorizing the tenderer, should be enclosed in the tender (in Cover-'A') duly signed by authorized signatory of the Drug Testing laboratory. Such authorized signatory of the tenderer should sign at the bottom of all the pages of the tender documents.

OTHER DOCUMENTS TO BE ENCLOSED: [self attested and notarized]

(j). Annual turnover statement certified by the auditors (C.A.) for last two years i.e., 2012-13 and 2013-14.

(k). Tenderer shall submit the checklist of documents in the enclosed performa in Annexure –VI

4. PRICE BID (COVER-'B')

(a). **Price Bid (Annexure VII)** of the tenderer duly filled in giving the rate of testing, charges for complete testing of each sample and signed on each page by authorized person with company seal, should be sent in separate sealed cover indicating name of the tenderer and superscribing "Price Bid" Cover –'B' hereafter called Cover-'B'.

(b). Cover-'B' shall contain the rates quoted by the tenderer only. It shall not contain any other document. No condition shall be indicated in the price bid. All the terms and conditions shall be indicated only in the technical bid.

(c). The tender documents and certificates must be submitted in a separate sealed cover as **Cover-'A'** and Price Bid shall be kept in separate sealed cover as **Cover-'B'**. Both **Cover-'A'** and **Cover-'B'** shall be kept in single sealed cover on which it shall be superscribed as "**TENDER FOR EMPANELMENT OF DRUGS TESTING LABORATORIES FOR ANALYSIS OF DRUGS & MEDICINES FOR TWO YEARS (2015-2017)**

(d). The tender document should reach **General Manager, BPPI, IDPL Corporate Office, IDPL Complex, Dundahera, Gurgaon-122016 (Haryana), till 25/03/2015 15.00 hour.**

(e). If the last date of submission is declared holiday, the tenders may be submitted on next working day upto 10.30 A.M.

(f). Tenderers should also enclose soft copy of Price Bid in CD along with Cover-'B'

5. GENERAL CONDITIONS

i. Forms in all annexure should be filled up properly. Every correction should invariably be attested by tenderer, failing which the tender will be summarily rejected.

ii. The tenderer should quote the rates for complete analysis as per the pharmacopoeial or other standards as per provisions of Drugs and Cosmetics Act 1940 for each drug and medicine not for individual test to be performed.

iii. The rates should be exclusive of taxes.

iv. The rates quoted and accepted will be binding on the tenderer for stipulated period and on no account any revision will be entertained till the completion of the contract period.

v. If in any circumstances (like breakdown of instrument or non-availability of reference standard and impurities etc.) the Drug Testing Laboratory is unable to test sample of Medicines, the same should be reported within 24 hours from time of breakdown of instrument or non-availability of reference standard of such sample by fax/ e-mail to Manager Regulatory.

vi. The tender submitted by the laboratory which has been blacklisted by the State / Central Govt. organization, shall not be considered.

vii. The laboratory will not be permitted to outsource any test from other Drug Testing laboratory.

6. ACCEPTANCE OF TENDER

i. Out of two covers submitted by each tenderer, Cover- 'A' will be opened first at **15.30 hours on 25/03/2015** in the presence of tenderers or their authorized representatives who chooses to be present. After scrutiny of the documents and information furnished in Cover-'A' and confirmation of details stated therein, a list of eligible laboratories will be shortlisted.

ii. Cover-'B' (Price Bid) of the tenderers found eligible on the basis of scrutiny of Cover-'A' will be opened subsequently and the date and time for opening of Cover-'B' will be intimated to the shortlisted tenderers. The acceptable rates for analysis will be decided on the basis of L1 rates and will be communicated.

iii. The tenderers other than L1 tenderer will be given opportunity to match L1 rate and after due confirmation, their name/s will be included in the panel. If required, the empanelled laboratories will be inspected by team of officials of BPPI as and when need arises.

iv. The tender inviting authority, BPPI reserves the right to accept or reject any tender for any one or more of the items tendered for, without assigning any reason.

v. No tenderer will be allowed to withdraw their bid after opening of Price Bid.

7. AGREEMENT

All tenderer who are empanelled will have to execute an agreement on non-judicial stamp paper of Rs. 100/-(stamp duty to be paid by tenderer) in favour of BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA within 15 days from the date of intimation received by them from BPPI that their tenders have been accepted. The form of agreement is enclosed in tender document.

8. SECURITY DEPOSIT

The successful tenderers must pay a security deposit of Rs. **20,000/-**(Rupees Twenty Thousand only) including adjustment of EMD amount at the time of execution of agreement referred in Para 7 above by way of DD in favour of BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA payable at Delhi/Gurgaon.

9. COMPLETE ANALYSIS AND REPORTING CONDITION

(a). On empanelment and entrustment of the job, the Drug Testing Laboratory should furnish the test reports within,

(i). 8 days of receipt of sample in case of Tablet, Capsules, Ointment, Cream, Gel, Powder and Liquid oral preparations (all non-sterile dosage forms).
(ii). 21 days of receipt of sample in case of LVP/SVP, Inject able in vial/Ampoules and Dry Powder Injectable (all sterile dosage forms).
(iii). Within 24 hours of receipt of sample, the confirmation of receipt should be given to BPPI by fax / mail.

(iv). For any delay more than stipulated time as mentioned in para 9 (a)(i) and (ii) as the case may be, 5% of testing charges per week and the part thereof would be deducted as penalty. For consecutively delay for 4 times or more than 8 times in a year or a delay of more than 10 days occurs over the time period stipulated above, then the penalty would be 10% of testing charges per week and part thereof.

(b). All the test mentioned under IP, BP, USP and any other standard mentioned as per Second Schedule of under D& C Act 1940 and Rules 1945 as well as Schedule V should be carried out for each and every sample. The results obtained in the test should be mentioned in figures. Test reports not mentioning complete details as per IP, BP, and USP etc will be considered as "Incomplete test report" and the drugs testing laboratory will have to submit complete report for acceptance.

(c). "Complies" or "Passes" or "Within Limit" in result column of the test report will also be treated as incomplete test report, if the result has some value the actual value found on analysis is to be reported.

(d). Every test report must have some specific remarks as 'Standard Quality', or 'Not of Standard Quality.' Any ambiguity/ cutting will not be accepted.

(e). Test report should have Sr. No., Description of tests, Specifications and Results obtained including protocol of test applied.

(f). Spectra/Chromatograph/Dissolution profile, or other data sheets, wherever applicable, should be attached with the test report.

(g). In the case of non-pharmacopoeial products the method of analysis should be mentioned in the report AND PROTOCOL OF TEST APPLIED TO BE MENTIONED ON EACH REPORT,

(h). The test report should be sent to Manager (Regulatory), BPPI office as hard copy and simultaneously scanned copy should be sent by e-mail **mahadevpharm.bppi@gmail.com**.

(i). All test report should be submitted to BPPI in duplicate. In case of failure of sample, result should be communicated immediately to Manager (Regulatory), BPPI through phone/ fax/ e-mail and physical report should be sent with covering letter addressed to Manager (Regulatory) at Bureau of Pharma Public Sector Undertakings of India (BPPI), IDPL Corporate Office, IDPL Complex, Dundahera, Gurgaon-122016 (Haryana).

(j). If in any circumstances (like breakdown of instrument or non-availability of reference standard etc.) the Drug Testing Laboratory is unable to undertake sample, the same should be reported within 24 hours of receipt of such sample by fax/ e-mail to Manager Regulatory and sample should be returned to him immediately. 100% of charges as penalty will be imposed in case no prior information of breakdown of instrument or non-availability of reference standard before sending samples. Refer para (5)(v).

(k). If any sample is received in damaged condition by the laboratory, the sample should not be analyzed and should be sent back immediately to Manager (Regulatory), BPPI and due information should be given by fax/ e-mail.

(l). Manager (Regulatory), BPPI or authorized representatives have the right to inspect the laboratories of the tenderer who have submitted tenders before taking any decisions regarding empanelment. He may also inspect any laboratory which is empanelled at any time during continuance of tender and initiate action to terminate / cancel its empanelment and not to entrust any further testing job to the laboratory if any violation of tender conditions are noticed during such inspections.

10. PAYMENT PROVISIONS

i. No advance payment towards any analysis will be made to tenderer.

ii. No payment will be made for incomplete analysis or incomplete report. Refer Para 9 (b) to 9 (g)

iii.(a). Payments towards the analysis of DRUGS & MEDICINES will be made along with tax at the prevailing rate as applicable at the time of payment strictly as per rules

(b). Bills should be supported with the copy of test report. Efforts will be made to make payments within 30 days from the date of receipt of the bills by BPPI if same are found in order in all respect.

11. PENALTIES PROVISIONS

If the successful tenderer fails to execute the agreement and payment of security deposit after opening of Price Bid within the specified time or withdraws the tender after the intimation of acceptance of tender has been received by them or owing to any other reasons, the tenderer is unable to undertake the contract, the empanelment will be cancelled and security deposit shall stand forfeited to BPPI. Such tenderer will also be liable for all damages sustained by BPPI by reasons of breach of tender conditions. Such damages shall be assessed by CEO, BPPI whose decision shall be final.

12. BLACK LISTING PROCEDURE

(a). Non performance of any tenderer or empanelment conditions will disqualify a laboratory to participate in the next tender.

(b). To assess the correctness of the test results given by the empanelled Drug testing laboratory, samples would also be taken and sent randomly to Govt. laboratory/ CPSUs Laboratories/ any other NABL accredited labs which are not empanelled for testing and if any variation in the results is found, the result would be informed to empanelled laboratory. If there is any major variation in the analytical reports furnished by empanelled laboratories, (either pass or fail etc.) viz-a-viz Govt. /CPSUs Laboratory/ any other NABL accredited labs, the empanelled laboratory will be blacklisted for two years besides forfeiture of security deposit, after giving due opportunity to the concerned laboratory.

(c). If it is revealed that Drug Testing Laboratory is involved in any form of fraud and collusion with the suppliers of BPPI, the Drug Testing Laboratory will be black listed for five years. The tenderer shall also be liable for action under criminal law and matter will be informed to relevant appropriate authorities for penal action against them.

(d). The CEO, BPPI will be at liberty to terminate the empanelment without assigning any reasons. The tenderer will not be entitled for any compensation whatsoever in respect of such termination.

Note:

- In all matters pertaining to tender, the decision of CEO, BPPI shall be final and binding.
- In event of any dispute arising out of tender, such dispute would be subject to the jurisdiction of civil court within Delhi.

- In case of dispute or difference arising between BPPI and empanelled Drug Testing Laboratory relating to any matter arising out of or connected with this tender agreement, such dispute or differences shall be settled in accordance with the Arbitration and Conciliation Act 1996. The venue of arbitration shall be Gurgaon.

13. AGREEMENT FORMAT (Contract for Empanelment of Drugs Testing Laboratories for the Analysis of DRUGS & MEDICINES)

Agreement made this _____ day of 2015 at BPPI Gurgaon between M/s _____ having its registered office at _____ (hereafter referred to as 'The Laboratory' which term should include its successors, representatives, hires, executors, and administrators unless excluded by contract) on one part and BPPI having its registered office at New Delhi on other part.

Whereas the Laboratory has agreed to undertake the analytical work of the BPPI, (the list of medicines mentioned in the Schedule attached hereto) at the rates noted therein and in the manner and under the terms and conditions hereinafter mentioned.

And whereas the Laboratory has deposited with the BPPI a sum of Rs 20000/- (Rupees Twenty thousand only) as Security Deposit for the due and faithful performance of this Agreement, to be forfeited in the event of the Laboratory failing duly and faithfully to perform it.

Now these presents witness that for carrying out the said Agreement in this behalf into execution, The Laboratory and the BPPI do hereby mutually convenient, declare, contract and agree each of them with the other of them in the manner following, that is to say,

(1). The term "Agreement", wherever used in this connection, shall mean and include the terms and conditions in tender floated by the BPPI for Empanelment of Drugs Testing, laboratories for the analysis of DRUGS & MEDICINES for the two years 2015-2017 the instructions to tenderer, the conditions of tender, acceptance of tender particulars hereinafter defined and those general and special conditions that may be added from time to time.

(2). (a). The Agreement is for undertaking analysis of DRUGS & MEDICINES by the Laboratory to the BPPI of the samples specified in the Schedule attached hereto at the rates noted against each therein on the terms and conditions set forth in the Agreement.

(b). This Agreement shall be deemed to have come into force with effect from _____ and it shall remain in force for a period upto date of _____ and may however be extended for a further period, on mutually agreed terms.

INSPECTION OF LABORATORY:

(3). In respect of the analysis medicines in the Schedule, the drug testing Laboratory shall allow inspection of the Laboratory at any time during the tender period by a team of Experts/Officials whom the BPPI may depute for the purpose. The Laboratory shall extend all facilities to the team to enable them to inspect premises, testing faculties, technical personals, reference standards/ working standards/ documentation as mandatory under D & C Act 1940 and Rules 1945, in the Laboratory.

RECOVERY OF MONEY DUE TO BPPI FROM THE LABORATORY:

(4). All expenses, damages and other money payable to the BPPI by the drug testing Laboratory under any provisions of this Agreement may be recovered from the amount due or subsequently becoming due from the BPPI to the Laboratory under this or any other Agreement. In case such amounts are insufficient to fully cover such expenses, damages or other money payable, it shall be lawful for the BPPI to recover the balance amount from the security deposit of the Laboratory and all other money held by BPPI and in case such Security Deposit is insufficient, then it shall also be lawful for the BPPI to recover the residue of the said expenses, damages and moneys, if necessary, by resorting to legal proceedings against the Laboratory.

AMOUNT OF SECURITY DEPOSIT TO BE MADE BY THE LABORATORY:

(5). The Laboratory shall deposit with the BPPI Rs. 20,000/- as security deposit by way of Demand Draft favoring BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA payable at Delhi/Gurgaon. This agreement comes into effect only after the laboratory has remitted the required amount of security deposit, not withstanding anything contained in Para 2 (b) of this agreement.

SUBMISSION OF BILLS FOR UNDERTAKING ANALYSIS:

(6).(a). No advance payment towards any analysis will be made to the Laboratory.

(b). All bills/invoices should be raised in duplicate in the name of Manager (Regulatory), BPPI. All payments shall be made by way of cheque drawn in favour of Laboratory account and Crossed Account Payee / NEFT only. The Laboratory shall furnish the details of their bank account no., name of bank and branch, IFSC code no. etc to the BPPI. (An original cancelled cheque leaf issued by their bank should be furnished).

ASSIGNMENT OF CONTRACT PROHIBITED:

(7). The Laboratory shall not, at any time, assign, sub-let or make over the present contract or the benefits thereof or any part thereof, to any person or persons whomsoever.

TERMINATION OF CONTRACT ON BREACH OF CONDITION:

(8).(a). In case the Laboratory fails or neglects or refuses to faithfully perform any of the covenants on his part herein contained or violates the condition in the tender document, it shall be lawful for BPPI to forfeit the amount deposited by the laboratory as security deposit and cancel the contract apart from black listing the laboratory for period of two years.

(b). In case of laboratory fails or refuses to observe, perform, fulfill and keep all or any other or more or any part of anyone of covenants, stipulations and provisions herein contain, it shall be lawful for BPPI on any such failure, neglect or refusal to put an end to this agreement and there upon every article clause and thing herein contained on the part of BPPI shall cease and be void and in case of any damage, loss, expense, differences in the cost or other moneys than or any time during the continuance of this agreement becoming due or owing by the laboratory to BPPI, it will be opened for BPPI to

recover from laboratory all such damages, losses, expenses, differences in cost or other moneys as aforesaid it shall be lawful for BPPI to appropriate the security deposit made by laboratory as herein before mentioned to reimburse all such damages, losses, expenses differences in cost and other moneys as BPPI have sustained, incurred or put to by reason of the laboratory having seen quality of any such failure, negligence or refusal as aforesaid or other breach in the performance of contract.

(c). If at any time during the course of contract it is found that information given by the laboratory to BPPI, either in tender or otherwise, is false, BPPI may put an end to contract / agreement wholly or in part and thereupon the provisions of cause (a) shall apply.

(9). The BPPI reserves the right to terminate without assigning any reasons therefore the contract/ agreement either wholly or in part without any notice to the laboratory. The laboratory will not be entitled for any compensation whatsoever in respect of such termination of contract by BPPI.

NOTICES ETC., IN WRITING:

(10). All certificates or notices or orders for the time or for extra , varied or altered laboratory, which are to be the subject of extra or varied charges whether so described in the agreement or not, shall be in writing and unless in writing shall not be valid, binding or be or any effect whatsoever.

LABORATORIES NOT TO HAVE ANY INTEREST IN THE OFFICERS CONCERNED AND SUBORDINATED:

(11). The laboratory shall not be in any way interested in or concerned directly or indirectly with any of the officers, subordinates or servants of BPPI in trade, business or transactions nor shall the laboratory give or pay or promise to give or pay any such officer, subordinate or servant directly or indirectly any money or fee or other consideration under designation of custom or otherwise nor shall the laboratory permit any person or persons whomsoever to interfere in the management or performance thereof under power of attorney or otherwise without obtaining the consent of BPPI in writing.

BANKRUPTCY OF THE LABORATORY:

(12). In case the Laboratory at any time during the continuance of the Contract becomes bankrupt or insolvent or commits any act of backrupcy or insolvency under the provisions of any law in that behalf for the time being in force, or should compound with his creditors, it shall be lawful for the BPPI to put an end to the Agreement, and thereupon every article, clause and thing herein contained to be operative on the part of the BPPI, shall cease and be void and the BPPI shall have all the rights and remedies given to him under the precedent clauses.

SERVING OF NOTICES TO LABORATORY:

(13). All notices or communications relating to or arising out this agreement or any of the terms thereof shall be considered duly served on or given to the laboratory if delivered to him or left at his premises, place of business or above.

(14). And it is hereby agreed and declared between the parties hereto that in case any question of dispute arises touching the construction or wording of any Para herein contained on the rights, duties, liabilities of the parties hereto or any other way, touching or arising out of the presents, the decision of CEO, BPPI in the matter shall be final and binding.

(15). In the event of any disputes between the parties the dispute would be subject to the jurisdiction of civil courts within Delhi only.

In witness where the laboratory and CEO, BPPI acting for and on behalf of BPPI have set their hands the day, month and year written above.

Authorized Signature of BPPI	**Authorized Signature of Laboratory**
Name	Name
Address and Seal	Address and Seal
Witnesses for BPPI	Witnesses for Laboratory
Signature	Signature
Name	Name
Address	Address

ANNEXURE-I

Proforma for Performance Statement

(1). Name of Laboratory:

(2). Address:

(3). Performance Statement:

Sr. No.	Category	No. of samples (complete analysis) tested during		Total no. of Samples
		2012-13	2013-14	
1	Tablets			
2	Capsules			
3	LVP / SVP			
4	Dry Powder Injectables (DPI)			
4	Liquid Orals/Syrups			
6	Ointments/ Creams/ Gel			
7	Eye/Ear Drops / Nasal Drops			
8.	Vaccines & Sera			
9.	Others			

Note: Facilities for LAL test if available Yes/ NO

ANNEXURE-II

Details of Laboratory and Certificate of Registration for Service Tax

(1). Name of Laboratory

(2). Address of Head Office, if any:

(3). Address of Laboratory

(4). Name of contact person

(5). Phone No. :

Mobile No.:

(6). E-mail :

(7). Details of Approval/ License issued by Drugs Regulatory Authority*

(8). Validity of Approval/ License issued by Drugs Regulatory Authority:

(9). NABL Certificate No. along with discipline*

(10). Validity of NABL Certificate:

(11). Certificate of Registration for Service Tax: To be enclosed

(12). Any other certificates with details*

* enclose duly attested copy

ANNEXURE-III-A

Personnel in Laboratory

1) Total qualified technical personnel engaged in Chemical / Instrumental analysis:

2) Total qualified technical personnel engaged in Microbiological analysis:

3) Details of Competent (Approved) staff by State Licensing Authority

S. No.	Name	Designation	Qualifications	Approval in Chemical / Instrumental/ Microbiological Testing	Experience in relevant analysis (Years)

ANNEXURE-III-B

List of all functional Sophisticated Instruments/ Apparatus including used for testing of Insulin, vaccines & sera etc.

S. No.	Name of Instrument/ Apparatus	Total Number	Make	Date of Installation

Enclose additional paper

ANNEXURE-III-C

Facilities in Microbiological Section with AHU in Laboratory

1) List of reference cultures available: To be given
2) List of reference impurities available: To be Given
3) List of reference standard/ working references available: To be Given
4) Details of equipments (e.g. Incubators, Laminar Air Flow etc.)

S. No.	Name of Instrument/ Apparatus	Total Number	Make	Date of Installation

Enclose additional paper

ANNEXURE-IV

Declaration Form (To be attested by Notary)

I / We _(Name of Bidder)_____having our Head Office at _____ and Drug Testing Laboratory at _____ do hereby declare that I / we have carefully read all the conditions of the tender of Bureau of Pharma Public Sector Undertakings of India (BPPI), Gurgaon for empanelment of Drugs Testing Laboratories for analysis of DRUGS & MEDICINES for two year period (2015-2017) and abide by all conditions said therein.

I/We further declare that we have valid approval/ license issued by Drug Regulatory Authority bearing no. _____ and NABL Certificate bearing no. _____ in discipline _____.

Signature

Name of Authorized Person
Seal of Laboratory

Annexure – V

List of DRUGS & MEDICINES

Tender for Empanelment of Analytical Testing Laboratories for the Analysis of Medicines for THE YEAR 2015-2017

Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Quoted By as Symbol (√) or yes
(1)	(2)	(3)	(4)	(5)
1	142	Insulin Injection (Human) I.P. strength 40iu/ml	10 ml Vial	
2	143	BIPHASIC INSULIN ASPART INJECTION IP 100 IU/ML (30:70)	VIAL	
3	153	CISPLATIN INJECTION IP 10 MG	VIAL&WFI	
4	162	Raloxifene Tablets strength 60 mg	10x10	
5	197	Lactulose Syrup strenth 10 g/15 ml	100 ml bottles	
6	276	Enoxaparin Injection I.P. strength 40mg/0.4ml	0.4 ml	
7	277	Enoxaparin Injection I.P. strength 60 mg/0.6 ml	0.6 ml	
8	280	Heparin Sodium Injection I.P.	5 ml	
9	359	TETANUS VACCINE (Adsorbed) IP	AMP 0.5 ML	
10	360	Mifepristone 200 mg Tablets	1x10	
11	361	OXYTOCIN INJECTION IP 5 UNITS/ML	1 ML	
12	362	BIPHASIC ISOPHANE INSULIN INJECTION IP 4O IU/ML (50:50)	10 ML VIAL	
13	363	GLARGINE 100 IU INJECTION	CARTRIDGE/vial 3 ML	
14	364	GLIMEPIRIDE 2 MG + METFORMIN HYDROCHLORIDE 500 MG SR TABLETS	10's	
15	365	GLICLAZIDE 80 MG + METFORMIN HYDROCHLORIDE TABLETS 500 MG	10's	
16	366	GLIPIZIDE 5 MG + METFORMIN HYDROCHLORIDE 500 MG TABLETS	10's	
17	367	VOGLIBOSE TABLETS IP 0.3 MG	10's	
18	368	GLICLAZIDE TABLETS SR 60 MG	10's	
19	369	ACARBOSE TABLETS IP 50 MG	10's	
20	370	NEUTRAL PROTAMINATED HAGEDORN INJECTION 40 IU	10 ML VIAL	
21	371	VOGLIBOSE TABLETS IP 0.2 MG	10's	
22	372	METFORMIN HYDROCHLORIDE TABLETS IP PROLONG RELEASE 500 MG	10's	
23	373	ARTESUNATE INJECTION 60 MG	1 ML	
24	374	ARTEMETHER 80 MG + LUMEFANTRINE 480 MG SR TABLETS	6's	
25	375	QUININE TABLETS IP 300 MG FILM COATED TABLETS	10's	
26	376	IMIPENEM AND CILASTATIN INJ IP (500MG+500MG)	VIAL & WFI	
27	377	CLINDAMYCIN CAPSULES IP 300 MG	10's	

28	378	EACH KIT CONTAIN RIFAMPICIN TABLET IP 450MG, ISONIAZIDE TABLET IP 300MG ETHAMBUTOL TABLET IP 800MG AND PYRAZINAMIDE TABLETS IP 750MG	1's	
29	379	RIFAMPICIN and ISONIAZIDE TABLETS IP (450 MG+300 MG)	10's	
30	380	CLARITHROMYCIN TABLETS IP 500 MG	4's	
31	381	CEFIXIME 200 MG + OFLOXACIN 200 MG TABLETS	10's	
32	382	LINEZOLID TABLETS IP 600 MG	10's	
33	383	CEFPODOXIME 200 MG+ CLAVULANIC ACID 125 MG TABLETS	6's	
34	384	ITRACONAZOLE CAPSULES 100 MG	4's	
35	385	CEFIXIME 200 MG + CLAVULANIC ACID 125 MG (AS POT.CLAVULANATE)TABLETS	10's	
36	386	DIETHYLCARBAMAZINE TABLETS IP 50 MG	30's	
37	387	TERBINAFINE 250 MG TABLETS	7's	
38	388	EACH KIT CONTAIN RIFAMPICIN TABLET IP 450MG, ISONIAZIDE TABLET IP 300MG and ETHAMBUTOL TABLET IP 800MG	1's	
39	389	PENICILLIN G 400000 IU TABLETS	6's	
40	390	ETHAMBUTOL TABLETS IP 800 MG	10's	
41	391	MOXIFLOXACIN TABLETS 400 MG	5's	
42	392	GRISEOFULVIN TABLETS IP 250 MG	10's	
43	393	ACICLOVIR DISPERSIBLE TABLETS IP 800 MG	5's	
44	394	PYRANTEL PAMOATE ORAL SUSPENSION IP 250 MG/10 ML	10 ML	
45	395	CEFUROXIME 500 MG+ CLAVULANIC ACID 125 MG (AS POT.CLAVULANATE) TABLETS	6's	
46	396	AMPHOTERICIN B INJECTION IP. 50MG/ML	20 ML	
47	397	OXYTETRACYCLINE CAPSULES IP 250 MG	8's	
48	398	RIFAMPICIN TABLETS IP 450 MG	10's	
49	399	RIFAMPICIN, ISONIAZIDE and PYRAZINAMIDE TABLETS IP (120MG+50MG+300MG)	10's	
50	400	KETOCONAZOLE TABLETS IP 200 MG	10's	
51	401	AMOXYCILLIN 250MG WITH POTASSIUM CLAVULANATE 125MG TABLETS IP	6's	
52	402	AMOXYCILLIN and POTASSIUM CLAVULANATE TABLETS IP (875MG+125MG)	6's	
53	403	CLINDAMYCIN INJ IP 300 MG/2 ML	2 ML	
54	404	LINEZOLID INFUSION 600 MG/300 ML	300 ML	
55	405	OFLOXACIN INFUSION IP 200 MG /100 ML	100 ML	
56	406	ACICLOVIR INTRAVENOUS INFUSION IP 500 MG/VIAL	VIAL	
57	407	IVERMECTIN TABLETS 12 MG	10's	
58	408	BENZYLPENICILLIN INJECTION IP 0.6 MILLION UNITS	VIAL	
59	409	BENZYLPENICILLIN INJECTION IP 1.2 MILLION UNITS	VIAL	
60	410	TRASTUZUMAB INJECTION 440 MG with WFI	1's	
61	411	BEVACIZUMAB INJECTION 25 MG	1's	
62	412	AZATHIOPRINE TABLETS IP 50 MG	10's	
63	413	METHOTREXATE TABLETS IP 7.5 MG	10's	

64	414	TRANEXAMIC ACID 500 MG+ MEFENAMIC ACID 250 MG TABELTS	10's	
65	415	GLYCERYL TRINITRATE TABLETS IP 250 µg	25's	
66	416	PRAZOSIN TABLETS IP 5 MG	15's	
67	417	TELMISARTAN IP 40 MG+ AMLODIPINE 5 MG TABLETS	15's	
68	418	ROSUVASTATIN TABLETS IP 20 MG	10's	
69	419	HEPARIN SODIUM 50 IU/20 GM OINTMENT	20 GM	
70	420	ATORVASTATIN 10 MG+ CLOPIDOGREL 75 MG CAPSULES	10's	
71	421	NEBIVOLOL TABLETS IP 5 MG	10's	
72	422	TORASEMIDE TABLETS 10 MG	15's	
73	423	BISOPROLOL TABLETS 5 MG	10's	
74	424	CARVEDILOL TABLETS IP 3.125 MG	10's	
75	425	DILTIAZEM TABLETS SR 90 MG	10's	
76	426	ACENOCOUMAROL TABLETS 2 MG	30's	
77	427	S-AMLODIPINE TABLETS IP 2.5 MG	10's	
78	428	DIGOXIN TABLETS IP 250 µg	10's	
79	429	ATORVASTATIN 10 MG+ FENOFIBRATES 160 MG TABLETS	15's	
80	430	AMIODARONE TABLETS IP 200 MG	10's	
81	431	RAMIPRIL and HYDROCLORTHIAZIDE TABLETS IP (5MG+12.5 MG)	10's	
82	432	OLMESARTAN TABLETS 40 MG	10's	
83	433	ISOSORBIDE MONONITRATE TABLETS IP 30 MG	30's	
84	434	PROPRANOLOL TABLETS IP 40 MG	10's	
85	435	ROSUVASTATIN 10 MG + FENOFIBRATES 160 MG TABLETS	10's	
86	436	TELMISARTAN 40 MG+ CHLORTHALIDONE 12.5 MG TABLETS	10's	
87	437	NIFEDIPINE PROLONGED RELEASE TABLETS IP 20 MG	10's	
88	438	INDAPAMIDE TABLETS IP 1.5 MG	10's	
89	439	OLMESARTAN MEDOXOMIL 40 MG + HYDROCLORTHIAZIDE 12.5 MG TABLETS	10's	
90	440	METOPROLOL 50 MG + AMLODIPINE 5 MG TABLETS	7's	
91	441	LOSARTAN 50 MG+ AMLODIPINE 5 MG TABLETS	10's	
92	442	FENOFIBRATE CAPSULES IP 150 MG	10's	
93	443	ISOSORBIDE DINITRATE TABLETS IP 5 MG	50's	
94	444	ENALAPRIL 10 MG + HYDROCLORTHIAZIDE 25 MG TABLETS	30's	
95	445	OLMESARTAN 20 MG+ AMLODIPINE 5 MG TABLETS	10's	
96	446	AMLODIPINE 5 MG + HYDROCHLOROTHIAZIDE 12.5 MG TABLETS	10's	
97	447	MOXONIDINE TABLETS 0.3 MG	10's	
98	448	AMLODIPINE 5 MG+ RAMIPRIL 5 MG TABLETS	10's	
99	449	SPIRONOLACTONE TABLETS IP 25 MG	15's	
100	450	LABETALOL TABLETS IP 100 MG	10's	
101	451	STREPTOKINASE INJECTION IP 1500000 IU	10 ML & WFI	
102	452	WARFARIN TABLETS IP 5 MG	10's	

103	453	BISOPROLOL 5 MG+ HYDROCHLOROTHIAZIDE 6.25 MG TABLETS	10's	
104	454	VALSARTAN TABLETS IP 80 MG	10's	
105	455	VERAPAMIL TABLETS IP 80 MG	10's	
106	456	ATORVASTATIN TABLETS IP 40 MG	10's	
107	457	TORASEMIDE TABLETS 20 MG	10's	
108	458	LABETALOL INJECTION IP 5 MG/ML	4 ML VIAL	
109	459	HYDROQUINONE 2 % + MOMETASONE 0.1% + TRETINOIN 0.025 % CREAM	20 GM	
110	460	TERBINAFINE 1% w/w + CLOBETASOL 0.05 % w/w + OFLOXACIN 0.75 % w/w + ORNIDAZOLE 2 % w/w CREAM	15 GM	
111	461	BETAMETHASONE VALERAT 0.1 % w/w + NEOMYCIN SULFATE 0.5 % w/w CREAM	20 GM	
112	462	BETAMETHASONE VALERATE and CLIOQUINOL CREAM BP (0.12w/w+3%w/w)	30 GM	
113	463	MUPIROCIN OINTMENT IP 2 % w/w	5 GM	
114	464	DICYCLOMINE 10 MG + PARACETAMOL 325 MG + TRAMADOL 50 MG CAPSULES	10's	
115	465	DOMPERIDONE 30 MG+ PANTOPRAZOLE 40 MG CAPSULES	10's	
116	466	URSODEOXYCHOLIC ACID TABLETS IP 300 MG	10's	
117	467	DICYCLOMINE 10 MG+ MEFENAMIC ACID 250 MG TABLETS	10's	
118	468	BACILLUS CLAUSII SPORES ORAL SUSPENSION 2 Billion/ 5 ML	5 ML	
119	469	HEPATIC PROTECTORS SYRUP	200 ML	
120	470	PEPSIN 10 MG+ DIASTASE 50 MG ORAL LIQUID /5 ML	200 ML	
121	471	OXETACAINE 10 MG+ ALUMINIUM 291 MG + MAGNESIUM 98 MG /5 ML GEL	200 ML	
122	472	DOMPERIDONE 30 MG+ ESOMEPRAZOLE 40 MG CAPSULE	10's	
123	473	LEVOSULPIRIDE 75 MG+ PANTOPRAZOLE 40 MG CAPSULE	10's	
124	474	DOXYLAMINE SUCCINATE 10 MG+ PYRIDOXINE HCl 10 MG TABLETS	30's	
125	475	SUCRALFATE SUSPENSION 500 MG/5ML	200 ML	
126	476	LIQUID PARAFFIN 1.25 ML+ MILK OF MAGNESIA 3.75ML+ SODIUM PICOSULPHATE 3.33MG /5ML EMULSION	200 ML	
127	477	CLIDINIUM 2.5 MG+ CHLORDIAZEPOXIDE 5 MG FILM COATED TABLETS	15's	
128	478	SODIUM PICOSULPHATE 10 MG TABLETS	10's	
129	479	TRICHOLINE CITRATE 550 MG + SORBITOL 7.15 MG SYRUP/5 ML	200 ML	
130	480	LEVOSULPIRIDE 75 MG+ ESOMEPRAZOLE 40 MG CAPSULES	10's	
131	481	RIFAXIMIN TABLETS BP 40 MG	10's	
132	482	LEVOSULPIRIDE (SR) 75 MG+ RABEPRAZOLE (EC)20 MG 5 CAPSULE	10's	
133	483	LOPERAMIDE CAPSULES IP 2 MG	10's	
134	484	ESOMEPRAZOLE (ENTERIC COATED) TABLETS IP 40 MG	10's	
135	485	PROMETHAZINE (FILM COATED) TABLETS IP 25 MG	10's	
136	486	PANCREATIN 170 MG+ DIMETHICONE 80 MG TABLETS	10's	
137	487	DICYCLOMINE 10 MG + DIMETHICONE 40 MG /5 ML SUSPENSION	30 ML	
138	488	LANSOPRAZOLE CAPSULES IP 15 MG	10's	

139	489	SULFASALAZINE TABLETS BP 1000 MG ENTERIC COATED	10's	
140	490	SIMETHICONE 40 MG DROPS	15 ML	
141	491	ITOPRIDE TABLETS 50 MG	10's	
142	492	SULFASALAZINE TABLETS BP 500 MG ENTERIC COATED	10's	
143	493	ISPAGHULA HUSK IP 50 GM	50 GM	
144	494	ISPAGHULA HUSK IP 100 GM	100 GM	
145	495	FERROUS AMMONIUM CITRATE 160 MG + CYANO COBALAMINE 7.5 MCG + FOLIC ACID 0.5 MG/15ML SYRUP	200 ML	
146	496	DYDROGESTERONE TABLETS IP 10 MG	10's	
147	497	KIT OF MIFEPRISTONE 200 MG (1 TABLET) + MISOPROSTOL 200 MG (4 TABLETS)	1's	
148	498	FERROUS ASCORBATE 100MG WITH FOLIC ACID 1.5MG TABLETS	10's	
149	499	NORETHISTERONE TABLETS IP 5 MG	10's	
150	500	LEVO-THYROXINE TABLETS IP 100 MCG	100's in A Bottle	
151	501	BETAMETHASONE SODIUM PHOSPHATE TABLETS IP 0.5 MG	20's	
152	502	DEFLAZACORT TABLETS 6 MG	6's	
153	503	METHYLPREDNISOLONE SODIUM SUCCINATE INJECTION 1000 MG PER VIAL	VIAL & WFI	
154	504	NANDROLONE DECANOATE INJECTION IP 25MG/ML	2 ML	
155	505	CARBIMAZOLE TABLETS IP 10 MG	100's in Bottle	
156	506	LEVO-THYROXINE TABLETS IP 50 MCG	100's in Bottle	
157	507	CARBIMAZOLE TABLETS IP 5 MG	10's	
158	508	LEVETIRACETAM TABLETS 500 MG	10's	
159	509	HYDROXYCHLOROQUINE TABLETS IP 200 MG	10's	
160	510	PARACETAMOL 325 MG+ TRAMADOL 37.5 MG TABLETS	10's	
161	511	PARACETAMOL TABLETS IP 650 MG	15's	
162	512	ACECLOFENAC 100 MG + PARACETAMOL 325 MG + SERRATIOPEPTIDASE 15 MG TABLETS	10's	
163	513	PIROXICAM CAPSULES IP 20 MG	10's	
164	514	CHYMOTRYPSIN + TRYPSIN (1:6) ENTERIC COATED TABLETS 100K AU	20's	
165	515	MEFENAMIC ACID SUSPENSION 100 MG/5 ML	60 ML	
166	516	ACECLOFENAC TABLETS SR 200 MG	10's	
167	517	THIOCOLCHICOSIDE 4 MG+ ACECLOFENAC 100 MG TABLETS	10's	
168	518	BACLOFEN TABLETS IP 10 MG	10's	
169	519	KETOROLAC TABLETS DT 10 MG	10's	
170	520	MEFENAMIC ACID 500 MG+ PARACETAMOL 325 MG TABLETS	10's	
171	521	TRAMADOL TABLETS SR 100 MG	10's	
172	522	ALFACALCIDOL SOFT GELATIN CAPSULES 0.25 MCG	10's	
173	523	NAPROXEN TABLETS IP 500 MG	15's	
174	524	LIDOCAINE INJECTION IP 2 %W/V	30 ML VIAL	

175	525	DICLOFENAC 1.16 w/w+ LINCEED OIL3% w/w+ METHYL SALICYLATE 10% w/w+MENTHOL 5% w/w GEL	30 GM	
176	526	CHLORPHENIRAMINE 4 MG+ CODEINE 10 MG/5 ML SYRUP	100 ML	
177	527	AMMONIUM CHLORIDE 50 MG+ CHLORPHENIRAMINE MALETAE 2.5 MG+ DEXTROMETHORPHAN 5 MG+ GUAIFENESIN 50 MG / 5ML SYRUP	100 ML	
178	528	PARACETAMOL 500 MG+ PHENYLEPHRINE 10 MG+ CHLORPHENIRAMINE 2 MG TABLETS	10's	
179	529	LEVOSALBUTAMOL 1.25 MCG+ IPRATROPIUM 500 MCG RESPULES/2.5ML	2.5 ML	
180	530	FORMOTERAL 6 MG+ BUDESONIDE 200 MG ROTACAP	30's	
181	531	GUAIFENESIN 100 MG+ TERBUTALINE 2.5 MG+ BROMHEXINE 8 MG /10 MLSYRUP	100 ML	
182	532	SALMETEROL 50 MG+ FLUTICASONE 250 MG ROTACAP	30's	
183	533	BROMHEXINE 4 MG+ DEXTROMETHORPHAN 5 MG+ AMMONIUM CHLORIDE 50 MG /5 ML SYRUP	100 ML	
184	534	SALBUTAMOL 200 MCG + BECLOMETHASONE 100 MCG ROTACAP	30's	
185	535	TERBUTALINE 2.5 MG + BROMHEXINE 8 MG /10 ML SYRUP	100 ML	
186	536	PROMETHAZINE 1.5 MG + PHOLCODINE CITRATE 1.5 MG /5ML LINCTUS	60 ML	
187	537	SALBUTAMOL 1 MG+ AMBROXOL HYDROCHLORIDE 15 MG/5 ML SYRUP	100 ML	
188	538	THEOPHYLLINE TABLETS 400 MG	10's	
189	539	ACETYLCYSTEINE TABLETS 600 MG	10's	
190	540	LEVBUTEROL 1.25 MG+ BUDESONIDE 1MG REPSULE	2 ML	
191	541	ACEBROPHYLLINE CAPSULES 100 MG	10's	
192	542	SODIUM CHLORIDE 0.65% w/v NASAL DROPS	20 ML	
193	543	MENTHOL CINNAMON and PINE OIL SOFT CAPSULES	10's	
194	544	FLUTICASONE PROPIONATE RESPULE 0.5 MG/2ML	2 ML	
195	555	DOXOFYLLINE TABLETS IP 400 MG	10's	
196	556	MONTELUKAST 10 MG + FEXOFENADINE 120 MG TABLETS	10's	
197	557	TIOTROPIUM ROTOCAP 18 MCG	15's	
198	558	FLUTICASONE 50 MCG+ AZELASTINE 140 MCG NASAL SPRAY	120MD	
199	559	SALBUTAMOL 2MG + THEOPHYLLINE 100 MG TABLETS	30's	
200	560	FLUTICASONE PROPIONATE 50 MCG PER PUFF NASAL SPRAY	120 MD	
201	561	LEVOSALBUTAMOL 1 MG/5ML SYRUP	100 ML	
202	562	LORATIDINE TABLETS BP 10 MG	10's	
203	563	OXYMETAZOLINE 0.5 MG /ML NASAL DROPS	10 ML	
204	564	FORMOTERAL 12 MG + TIOTROPIUM 18 MG ROTOCAP	15's	
205	565	CICLESONIDE 400 MCG+ FORMOTEROL 12 MCG + TIOTROPIUM 18 MCG ROTOCAP	15's	
206	566	IPRATROPIUM 250 MCG/ML I:SOLUTION	15 ML	
207	567	SALBUTAMOL 100 MCG + IPRATROPIUM 20 MCG /PUFF INHALER	100 MD	
208	568	SALMETEROL 50 MCG+ FLUTICASONE PROPIONATE 250 MCG /PUFF INHALER	100 MD	

209	569	SILDENAFIL TABLETS IP 50 MG	4's	
210	570	TADALAFIL TABLETS 20 MG	4's	
211	571	TAMSULOSIN 0.4 MG + DUTASTERIDE 0.5 MG TABLETS	15's	
212	572	COMBINATIONS WITH TETANUS COMPONENT (DIPHTHERIA, TETANUS, PERTUSSIS, POLIOMYELITIS AND HAEMOPHILUS INFLUENZA) INJECTION	0.5 ML	
213	573	MONOCLONAL ANTI-D GAMAGLOBULIN INJECTION 300 MCG	1 ML with WFI	
214	574	VACCINE RABIES INJECTION 2.5 IU	1 ML	
215	575	VACCINE VARICELLA INJECTION	0.5 ML	
216	576	VACCINE HEPATITIS A INJECTION 80 IU	0.5 ML	
217	577	VACCINE STREPTOCOCCUS PNEUMONIAE POLYSACCHARIDE INJECTION 0.5 ML	0.5 ML	
218	578	VACCINE ROTA VIRUS LIVE ORAL	1 ML	
219	579	CALCIUM PANTOTHENATE 50MG+VIT B12 15 MCG+FOLIC ACID 1.5MG+THIAMINE MONONITRATE 10MG+RIBOFLAVINE 10MG+PYRIDOXINE HCL 3 MG+NIACINAMIDE 100 MG+ASCORBIC ACID 150MG +BIOTIN 100MCG CAPSULES	20's	
220	580	**G**inseng extract 42.5 mg, vitamin A 2500 IU, vitamin B1 1 mg, vitamin B2 1.5 mg, vitamin B6 1 mg, vitamin B12 1 mcg, vitamin C 50 mg, vitamin E 5 mg, vitamin D 200 IU, nicotinamide 10 mg, carbohydrates 0.1 g, folic acid 0.15 mg, ferrous fumarate 30 mg, copper 0.5 mg, potassium sulphate 2 mg, manganese 0.5 mg, magnesium sulphate 3 mg, zinc oxide 10 mg, calcium 75 mg, phosphate 58 mg, iodine 0.1 mg, protein 0.2 g, fat 0.38 g	10's	
221	581	CALCIUM CARBONATE 500 MG + CALCITRIOL 0.25 MCG + ZINC 7.5 MG	15's	
222	582	VITAMINS A,C,D,E,AND B COMPLEX AND MINERALS SYRUP	200 ML	
223	583	CYPROHEPTADINE TABLETS IP 4 MG	10's	
224	584	CALCIUM CITRATE MALATE 250 MG , VITAMIN D3 100 IU AND FOLINIC ACID 50 MCG TABLETS	30's	
225	585	VITAMIN D - CHOLECALCIFEROL 60000 IU /1 GM SACHET	1 SACHET	
226	586	METHYLCOBALAMIN 1500 MCG, L- CARTININE L- TARTRATE 500 MG, FOLIC ACID 1.5 MG TABLETS	10's	
227	587	APPETITE ENHANCER (PEPTONE, MINERALS, VITAMINS)SYRUP	300 ML	
228	588	VITAMIN E SOFTGEL CAPSULES 400 MG	10's	
229	589	CALCIUM 500 MG+ CALCITRIOL 0.25 MG TABLETS	15's	
230	590	VITAMIN A, B-COMPLEX, D & E INJECTION	10 ML VIAL	
231	591	METHYLCOBALAMIN 500 MCG INJECTION	1 ML AMPULE	
232	592	L-LYSINE + MULTIVITAMINS (VIT-B1,B2,B3,B5,B6) SYRUP	200 ML	
233	593	NICOTINAMIDE 200 MG+ FOLIC ACID 15 MG + CYANOCOBALAMIN 0.5 MCG INJECTION	10 ML	
234	594	GLUCOSE D POWDER	100 GM	
235	595	THIAMINE 100 MG+ PYRIDOXINE HCl 50 MG + CYANOCOBALAMIN 1000 MCG INJECTION	2 ML	
236	596	ZINC SULPHATE 20 MG/ ML ORAL SOLUTION	15 ML	
237	597	VITAMIN B6 TABLETS IP 5 MG	10's	
238	598	PREGABALIN 75 MG+ METHYLCOBALAMIN 750 MCG TABLETS	10's	
239	599	PREGABALIN TABLETS 75 MG	10's	

Annexure – VI

CHECK LIST

S. No.	Particulars	Page No.	Yes	No
1.	Annexure VI - Checklist			
2	EMD in the form of DD shall be kept in an envelope.			
3	Self attested and notorised Photo copy of licence for Drug Testing Laboratory renewed upto date.			
4	Recognition Certificate issued by NABL			
5	Annual Turn over for the last two years certified by the auditors.			
6	*GLP compliant under the provisions of Drugs & Cosmetics Act 1940 and Rules 1945 (Schedule L1 certificate.*			
7	Certificate for analysis issued by other recognized agencies			
8	Annexure – I Proforma for performance statement			
9	Annexure – II Details of Laboratory and Certificate of Registration for service tax			
10	Annexure – III (A) Personnel in Laboratory.			
11	Annexure – III (B) List of Sophisticated instruments.			
12	Annexure – III (C) Facilities in Microbiological section			
13	Annexure – IV Declaration form duly signed & notarized.			
14	Annexure – V List of DRUGS & MEDICINES			
15	Documentary evidence, for the constitution of the company / laboratory ie., Memorandum and articles of Association or partnership etc.,			
16	The instruments such as power of attorney, resolution of board etc.,			
17	The tender document signed by the tenderer in all pages with official seal			
18	Documentary evidence of having analyzed drugs for the test for the last two years			
19	Cover B: Annexure – VII (Price Bid) Hard and softcopy in a separate cover			

Annexure – VII

Price Bid

S. No.	Drug Code	Name of Medicine	Unit Size	Rate excluding Tax	Tax applicable in %	Total including Taxes	Remarks
1							
2							
3							
4							
5							
6							
7							

Enclose Soft Copy of Price Bid (in Excel Sheet) in CD also.